Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 31.24
(-0.13%)
CNY 31.24
(-0.13%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.34 Billion CNY | 10.91% |
| 2022 | 3.01 Billion CNY | 8.73% |
| 2021 | 2.77 Billion CNY | 9.66% |
| 2020 | 2.53 Billion CNY | 156.4% |
| 2019 | 987.08 Million CNY | 25.0% |
| 2018 | 789.69 Million CNY | 33.4% |
| 2017 | 591.97 Million CNY | 13.79% |
| 2016 | 520.21 Million CNY | 66.94% |
| 2015 | 311.62 Million CNY | 10.08% |
| 2014 | 283.09 Million CNY | 11.08% |
| 2013 | 254.86 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 3.41 Billion CNY | -2.73% |
| 2024 Q1 | 3.37 Billion CNY | 0.83% |
| 2024 Q2 | 3.51 Billion CNY | 4.14% |
| 2023 Q2 | 3.08 Billion CNY | -0.43% |
| 2023 FY | 3.34 Billion CNY | 10.91% |
| 2023 Q3 | 3.21 Billion CNY | 4.23% |
| 2023 Q1 | 3.09 Billion CNY | 2.69% |
| 2023 Q4 | 3.34 Billion CNY | 4.07% |
| 2022 Q2 | 2.9 Billion CNY | 1.45% |
| 2022 Q1 | 2.86 Billion CNY | 3.12% |
| 2022 FY | 3.01 Billion CNY | 8.73% |
| 2022 Q4 | 3.01 Billion CNY | 0.47% |
| 2022 Q3 | 3 Billion CNY | 3.45% |
| 2021 FY | 2.77 Billion CNY | 9.66% |
| 2021 Q4 | 2.77 Billion CNY | 1.28% |
| 2021 Q1 | 2.55 Billion CNY | 1.0% |
| 2021 Q2 | 2.58 Billion CNY | 0.96% |
| 2021 Q3 | 2.74 Billion CNY | 6.19% |
| 2020 Q2 | 1.1 Billion CNY | 13.99% |
| 2020 FY | 2.53 Billion CNY | 156.4% |
| 2020 Q3 | 2.4 Billion CNY | 118.95% |
| 2020 Q4 | 2.53 Billion CNY | 5.08% |
| 2020 Q1 | 965.02 Million CNY | -2.23% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 987.08 Million CNY | 25.0% |
| 2019 Q4 | 987.08 Million CNY | 0.0% |
| 2018 FY | 789.69 Million CNY | 33.4% |
| 2017 FY | 591.97 Million CNY | 13.79% |
| 2016 Q2 | 358.82 Million CNY | 0.0% |
| 2016 Q1 | 358.82 Million CNY | 15.15% |
| 2016 FY | 520.21 Million CNY | 66.94% |
| 2015 Q4 | 311.62 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 311.62 Million CNY | 10.08% |
| 2014 FY | 283.09 Million CNY | 11.08% |
| 2013 FY | 254.86 Million CNY | 0.0% |